tercica_hp_logo
tercica_requesttercica_contact tercica_signup
Tercica Home About Tercica Tercica Products Pipeline Tercicare tercica_nav_investors Join the Tercica Team Tercica Partners
 
Financial Information

Investor Resources
Delivering Value
Ideally positioned in a growing market
Tercica is committed to serving our existing and prospective shareholders. Our company strives to deliver value and financial success through a team of people who are dedicated to cultivating strong relationships with members of our investment community. View our financial calendar or sign up for e-mail alerts and let us keep you updated on Tercica's current news and financial forecasts.

We invite you to email our Investor Relations team or call (650) 624-4992 for more information. You may also write to:

Tercica, Inc.
Corporate Headquarters
2000 Sierra Point Parkway, Suite 400
Brisbane, CA 94005
Attn. Fredrik Wiklund, Senior Director, Investor Relations
Stock Info
$8.97 ( 0.11)
Volume  0
Day High  $8.98
Day Low  $8.85
6:41 AM ET - 10/20/08
SEC Filings
Oct 29, 2008
effectiveness order
Oct 29, 2008
effectiveness order
Quarterly Earnings
Tercica Reports Second Quarter 2008 Financial Results
View Press Release
First Quarter 2008 Financial Results
Listen to Webcast
Tercica Reports First Quarter 2008 Financial Results
View Press Release
Form 10-Q
View SEC Filing
Annual Reports
2007 annual report
2006 annual report
Financial Calendar
There are no events currently scheduled.
Press Releases
Nov 12, 2008
Tercica Announces Results from Increlex(R) Phase IIIb Study Demonstrating Dose-Dependent Height Velocity Increase in Primary IGFD Short Stature Population and Other Increlex(R) Studies at the 13th International Congress of Endocrinology Meeting

Jul 31, 2008
Tercica Reports Second Quarter 2008 Financial Results

Tercica Fact Sheet
This information is currently being updated, please check back soon
Webcast Replays
There are no replays available at this time.
Corporate Presentations
May. 13, 2008
Corporate Presentation
Analyst Coverage
Andrew Fein
Jim Reddoch
Matthew Osborne
Jim Birchenough, M.D.
Christopher Raymond
Eric Schmidt, Ph.D.
Track our progress
Track our progress